Harrow Health Inc's stock experienced a significant after-hours plunge of 7.99%, following the release of its first-quarter 2026 financial results.

The company reported a quarterly loss of $0.74 per share, which missed analyst consensus estimates by 89.74%. Revenue for the quarter came in at $44.2 million, falling short of expectations by 15.68% and representing a 7.59% decline year-over-year. The net loss widened to $27.6 million, while gross margin contracted to 61% from 68% in the same period last year.

Management attributed part of the revenue shortfall to a non-recurring $8 million gross-to-net adjustment related to new commercial coverage for its VEVYE product. Despite the disappointing quarterly results, the company reaffirmed its full-year 2026 revenue guidance of $350 million to $365 million and projected improved second-quarter revenue between $71 million and $81 million.